Spark Therapeutics and Pfizer have entered into an amendment to their license agreement for SPK-9001, an investigational gene therapy for hemophilia B.
Spark Therapeutics will enroll up to five additional participants in the current Phase 1/2 clinical trial who will receive SPK-9001 manufactured using an enhanced process to test its comparability to the SPK-9001 received by the first 10 participants enrolled in the ongoing trial.
One of the up to five participants has already received SPK-9001 manufactured using the enhanced process. As of Oct. 23, this participant has been followed for 32 weeks post-infusion.
The participant's factor IX activity level has plateaued within the range that is considered comparable to the first 10 participants, and this participant's number of prophylactic intravenous factor IX infusions has been reduced to zero.
"Early data on the 11th participant suggest potential clinical comparability with the preliminary safety and efficacy results seen with the initial 10 trial participants, who all have discontinued routine infusions of factor IX concentrates," said Katherine A. High, M.D., president and head of Research & Development at Spark Therapeutics.
"We look forward to transitioning this program to Pfizer and potentially bringing to market this one-time investigational gene therapy for patients with hemophilia B, who otherwise rely on frequent infusions of factor IX to control and prevent bleeding episodes."
Updated data on all 11 participants in the Phase 1/2 clinical trial will be presented by Lindsey A. George, M.D., attending physician in the Division of Hematology at Children's Hospital of Philadelphia, at the 59thAmerican Society of Hematology (ASH) Annual Meeting & Exposition, at the Georgia World Congress Center in Atlanta on Monday, Dec. 11, at 7:00 AM ET.
Spark Therapeutics is transferring the enhanced SPK-9001 manufacturing process to Pfizer, which intends to utilize material generated with this process in the Phase 3 clinical trial of SPK-9001.
The activities outlined in the license agreement as amended will occur in parallel to Pfizer's ongoing preparation to assume responsibility for SPK-9001 after the transfer of the Investigational New Drug application to Pfizer.
Subject to the terms of the amendment, Spark Therapeutics will receive from Pfizer an initial $10 million cash payment and up to an additional $15 million in potential milestone payments upon completion of certain transition activities.
Hemophilia, a rare genetic bleeding disorder that causes the blood to take a long time to clot because of a deficiency in one of several blood clotting factors, is almost exclusively found in males. People with hemophilia are at risk for excessive and recurrent bleeding from modest injuries, which have the potential to be life threatening.
SPK-9001 is a novel, investigational bio-engineered adeno-associated virus (AAV) capsid expressing a codon-optimized, high-activity human factor IX variant enabling endogenous production of factor IX.
Spark Therapeutics and Pfizer entered into a collaboration in December 2014 for the SPK-FIX program, including SPK-9001, under which Spark Therapeutics is responsible for conducting all Phase 1/2 studies for any product candidates, while Pfizer will assume responsibility for pivotal studies, any regulatory activities and potential global commercialization of any products that may result from the collaboration.